世界の幹細胞市場2022-2030:製品別(成体幹細胞、ヒト胚性幹細胞)、用途別、技術別、治療別、最終用途別、地域別

【英語タイトル】Stem Cells Market Size, Share & Trends Analysis Report By Product (Adult Stem Cells, Human Embryonic Stem Cells), By Application, By Technology, By Therapy, By End Use, By Region, And Segment Forecasts, 2022 - 2030

Grand View Researchが出版した調査資料(GRV22NV085)・商品コード:GRV22NV085
・発行会社(調査会社):Grand View Research
・発行日:2022年10月7日
・ページ数:150
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:バイオ
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥880,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥1,028,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,324,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Grand View Research社は、世界の幹細胞市場規模が、2022年から2030年の間に年平均11.4%成長し、2030年までに316億ドルに達すると予測しています。当調査レポートでは、幹細胞の世界市場について総合的に調査・分析を行い、調査手法、市場定義、エグゼクティブサマリー、市場変動・動向・範囲、製品別(成体幹細胞、ヒト胚性幹細胞、人工多能性幹細胞、極小胚様幹細胞)分析、用途別(再生医療、創薬・開発)分析、技術別(細胞取得、細胞生産、凍結保存、拡大・継代培養)分析、最終用途別(製薬&バイオテクノロジー企業、病院&細胞バンク、学術&研究機関)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況などの構成でまとめています。なお、当書に掲載されている企業情報には、ADVANCED CELL TECHNOLOGY, INC.、STEMCELL Technologies, Inc.、CELLULAR ENGINEERING TECHNOLOGIES INC.、CELLGENIX GmbH、PROMOCELL GMBH、LONZA、KITE PHARMA、CELLARTIS AB、ANGEL BIOTECHNOLOGYなどが含まれています。
・調査手法
・市場定義
・エグゼクティブサマリー
・市場変動・動向・範囲
・世界の幹細胞市場規規模:製品別
- 成体幹細胞の市場規模
- ヒト胚性幹細胞の市場規模
- 人工多能性幹細胞の市場規模
- 極小胚様幹細胞の市場規模
・世界の幹細胞市場規規模:用途別
- 再生医療における市場規模
- 創薬・開発における市場規模
・世界の幹細胞市場規規模:技術別
- 細胞取得技術の市場規模
- 細胞生産技術の市場規模
- 凍結保存技術の市場規模
- 拡大・継代培養技術の市場規模
・世界の幹細胞市場規規模:最終用途別
- 製薬&バイオテクノロジー企業における市場規模
- 病院&細胞バンクにおける市場規模
- 学術&研究機関における市場規模
・世界の幹細胞市場規模:地域別
- 北米の幹細胞市場規模
- ヨーロッパの幹細胞市場規模
- アジア太平洋の幹細胞市場規模
- 中南米の幹細胞市場規模
- 中東・アフリカの幹細胞市場規模
・競争状況

Stem Cells Market Growth & Trends

The global stem cells market size is expected to reach USD 31.6 billion by 2030, registering a CAGR of 11.4% from 2022 to 2030, according to a new report by Grand View Research, Inc. Stem cells are cells that can differentiate into a variety of other cells, eventually forming organs or tissues. Many studies have been conducted over the years to assess the true potential of stem cells, leading to a variety of applications in the fields of genetic disease treatment, neurological disorders, oncology, and organ regeneration. The market is driven by the rising number of banks, growing focus on increasing therapeutic potential of these products, and extensive research for the development of regenerative medicines, among other factors.

The growing focus on regenerative therapies is fueling market expansion. iPSCs are becoming increasingly popular for the creation of customized cellular therapies, and opening up new possibilities in regenerative medicine. For instance, in September 2020, researchers from Duke-NUS and Monash University discovered the first stem cell that can aid in the treatment of placenta issues during pregnancy. The researchers devised a new method for producing induced trophoblast stem cells that can be used to generate placenta cells. The research will aid in the development of an in-vitro human placenta model and pave the way for future therapies.

Moreover, COVID-19 is acting as a catalyst for promoting the market growth. Several countries such as U.S., China, and Iran, have started conducting clinical trials using cellular therapies for treatment of COVID-19 infections. Furthermore, the use of cell therapy in the treatment of COVID-19 patients has yielded excellent results, which is fueling market expansion. In January 2020, a group of researchers in Beijing, China, tested stem cell treatment on patients to see if it was beneficial against COVID-19. The study found that administering intravenous clinical-grade MSCs to COVID-19 patients during first trial of treatment, improved their functional results and promoted enhanced recovery.

Increasing prevalence of cancer is one of the key factors contributing to the growth over the forecast period. Failure of combination therapy and chemotherapy for treatment of cancer has led to the shift in preference of physicians from such therapies to autologous and allogeneic stem cell therapy, thereby boosting the growth. Moreover, key market players and the government bodies are continuously investing in cancer research. For instance, in November 2021, California Institute for Regenerative Medicine invested USD 4 million in therapy targeting patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)

Introduction of novel technologies for the usage and adoption of cell based therapy is expected to boost the growth over the forecast period. Automation in adult stem cell & cord blood processing and storage are the key technologies expected to positively influence the market growth. For instance, various scientists are aiming for the approval of safe, and successful treatments using stem cells in a broad range of diseases. In 2021, companies such as Biotech Cellino invested USD 75 million in an effort to merge Artificial Intelligence technology for the development of automated stem cell manufacturing, that has the ability to regularizing access to cell treatments while aiming to be cost effective.

On the other hand, high cost of therapy is expected to hinder the market growth. For example, Bio informant, a stem cell research firm, reported that the cost of stem cell therapy ranges between USD 5,000 and USD 8,000 per patient, with some cases costing as much as USD 25,000 or more depending on the complexity of the procedure. Furthermore, restrictions on stem cell research activities have traditionally hampered embryonic stem cell growth, resulting in a meager share of the total market despite its advantages.

Stem Cells Market Report Highlights

• ASCs segment accounted for the largest share in 2021 as it is considered as a gold standard in stem cell-based therapies. They are widely accepted owing to their consistent clinical success especially in hematopoietic transplants and there is a relatively less controversial view regarding their origin

• The iPSC segment is expected to witness a lucrative CAGR through 2022-2030 owing to the increasing focus of companies in using iPS for cell therapies. For instance, in July 2020, Cynata Therapeutics Limited announced positive results for the phase 1 clinical trial of CYP-001, the company’s lead iPSC derived Cymerus

• Regenerative medicine dominated the market in 2021 owing to increasing funding by the government for the development of regenerative medicines. For instance, in October 2020, the AusBiotech-led consortium received funding of USD 300,000 from MTPConnect’s Industry Growth Centre Project Fund for the development of regenerative medicines in Australia

• Cell acquisition technology held the largest market share in 2021 and is expected to expand at the fastest CAGR through 2022-2030 owing to increasing research studies involving cell harvesting

• Allogenic therapy dominated the market in 2021 owing to the increasing application of allogeneic stem cell transplants for cancer treatment

• Pharmaceutical and biotechnology companies held the largest market share in 2021, and is anticipated to exhibit at fastest CAGR owing to upsurge in R&D, increasing clinical trials coupled with strategic activities by major market players

• North America market encompasses U.S. and Canada. The factors contributing to the market growth in the region include robust government funding, increasing research, and the presence of prominent players in this region

• Asia Pacific is expected to grow with the fastest CAGR of through 2022 to 2030 owing to increasing expansion by key companies in this region. For instance, in April 2020, Seneca Biopharma completed its new stem cell manufacturing facility in Suzhou, China

❖ レポートの目次 ❖

Table of Contents

Chapter 1 Research Technologyology
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Technologyology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List Of Abbreviations
Chapter 2 Market Definitions
Chapter 3 Executive Summary
3.1 Market Summary
Chapter 4 Global Stem Cells Market Market Variables, Trends, & Scope
4.1 Stem Cells Market Lineage Outlook
4.1.1 Parent Market Outlook
4.2 Penetration and Growth Prospect Mapping
4.3 Regulatory Framework
4.4 Market Driver Analysis
4.4.1 Ongoing Developments In Regenerative Medicine
4.4.2 Rising Funds For Accelerating Stem Cell Research
4.4.3 Growing Demand For Stem Cell Banking
4.4.4 Increasing Prevalence Of Genetic Disorders
4.5 Market Restraint Analysis
4.5.1 Ethical Concern Related To Stem Cell Research
4.5.1 Lack Of A Well-Defined Regulatory Framework In Certain Applications Of Stem Cell
4.6 Key Opportunities
4.6.1 Demand For Cell & Gene Therapies
4.7 Key Challenge
4.7.1 Technical Limitations Associated With Manufacturing Processes
4.8 Stem Cells Market – Pestle Analysis
4.9 Industry Analysis – Porter’s
4.10 Major Deals And Strategic Alliances Analysis
4.10.1 Joint Ventures
4.10.2 Mergers And Acquisitions
4.10.3 Licensing And Partnership
4.10.4 Technology Collaborations
4.10.5 Strategic Divestments
4.11 COVID-19 Impact Analysis
Chapter 5 Stem Cells Market – Segment Analysis, by Product, 2018 – 2030 (USD Million)
5.1 Global Stem Cells Market: Product Movement Analysis
5.2 Adult Stem Cells (ASCs)
5.2.1 Adult Stem Cells (Ascs) Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.2.2 Hematopoietic Stem Cells (Blood Stem Cells)
5.2.2.1 Hematopoietic stem cells (blood stem cells) market estimates and forecasts, 2018 – 2030 (USD Million)
5.2.3 Mesenchymal Stem Cells
5.2.3.1 Mesenchymal stem cells market estimates and forecasts, 2018 – 2030 (USD Million)
5.2.4 Neural Stem Cells
5.2.4.1 Neural stem cells market estimates and forecasts, 2018 – 2030 (USD Million)
5.2.5 Epithelial/Skin Stem Cells
5.2.5.1 Epithelial/Skin stem cells market estimates and forecasts, 2018 – 2030 (USD Million)
5.2.6 Other Adult Stem Cells
5.2.6.1 Other adult stem cells market estimates and forecasts, 2018 – 2030 (USD Million)
5.3 Human Embryonic Stem Cells
5.3.1 Human Embryonic Stem Cells Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.4 Induced Pluripotent Stem Cells
5.4.1 Induced Pluripotent Stem Cells Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.5 Very Small Embryonic Like Stem Cells
5.5.1 Very Small Embryonic Like Stem Cells Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 6 Stem Cells Market- Segment Analysis, by Application, 2018 – 2030 (USD Million)
6.1 Stem Cells Market: Application Movement Analysis
6.2 Regenerative Medicine
6.2.1 Regenerative Medicine Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.2.2 Neurology
6.2.2.1 Neurology market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.3 Orthopedics
6.2.3.1 Orthopedics market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.4 Oncology
6.2.4.1 Oncology market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.5 Hematology
6.2.5.1 Hematology market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.6 Cardiovascular and Myocardial Infraction
6.2.6.1 Cardiovascular and myocardial infraction market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.7 Injuries
6.2.7.1 Injuries market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.8 Diabetes
6.2.8.1 Diabetes market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.9 Liver Disorder
6.2.9.1 Liver Disorder market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.10 Incontinence
6.2.10.1 Incontinence market estimates and forecasts, 2018 – 2030 (USD Million)
6.2.11 Others
6.2.11.1 Others market estimates and forecasts, 2018 – 2030 (USD Million)
6.3 Drug Discovery and Development
6.3.1 Drug Discovery And Development Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 7 Stem Cells Market – Segment Analysis, by Technology, 2018 – 2030 (USD Million)
7.1 Global Stem Cells Market: Technology Movement Analysis
7.2 Cell Acquisition
7.2.1 Cell Acquisition Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.2.2 Bone Marrow Harvest
7.2.2.1 Bone Marrow Harvest market estimates and forecasts, 2018 – 2030 (USD Million)
7.2.3 Umbilical Blood Cord
7.2.3.1 Umbilical Blood Cord market estimates and forecasts, 2018 – 2030 (USD Million)
7.2.4 Apheresis
7.2.4.1 Apheresis market estimates and forecasts, 2018 – 2030 (USD Million)
7.3 Cell Production
7.3.1 Cell Production Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.3.2 Therapeutic Cloning
7.2.3.1 Therapeutic Cloning market estimates and forecasts, 2018 – 2030 (USD Million)
7.3.3 In Vitro Fertilization
7.3.3.1 In Vitro Fertilization market estimates and forecasts, 2018 – 2030 (USD Million)
7.3.4 Cell Culture
7.3.4.1 Cell Culture market estimates and forecasts, 2018 – 2030 (USD Million)
7.3.5 Isolation
7.3.5.1 Isolation market estimates and forecasts, 2018 – 2030 (USD Million)
7.4 Cryopreservation
7.4.1 Cryopreservation Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.5 Expansion And Sub-Culture
7.5.1 Expansion And Sub-Culture Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 8 Stem Cells Market – Segment Analysis, By Therapy, 2018 – 2030 (USD Million)
8.1 Global Stem Cells Market: Therapy Movement Analysis
8.2 Autologous
8.2.1 Autologous Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.3 Allogenic
8.3.1 Allogenic Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 9 Stem Cells Market – Segment Analysis, By End-User, 2018 – 2030 (USD Million)
9.1 Global Stem Cells Market: End-User Movement Analysis
9.2 Pharmaceutical And Biotechnology Companies
9.2.1 Pharmaceutical And Biotechnology Companies Market Estimates And Forecast, 2018 – 2030 (USD Million)
9.3 Hospitals & Cell Banks
9.3.1 Hospitals & Cell Banks Market Estimates And Forecast, 2018 – 2030 (USD Million)
9.4 Academic & Research Institutes
9.4.1 Academic & Research Institutes Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 10 Stem Cells Market: – Segment Analysis, By Region, 2018 – 2030 (USD Million)
10.1 Stem Cells Market: Regional Movement Analysis
10.2 North America
10.2.1 North America Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.2.2 U.S.
10.2.2.1 U.S. market estimates and forecast, 2018 – 2030 (USD Million)
10.2.3 Canada
10.2.3.1 Canada market estimates and forecast, 2018 – 2030 (USD Million)
10.3 Europe
10.3.1 Europe Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.3.2 U.K.
10.3.2.1 U.K. market estimates and forecast, 2018 – 2030 (USD Million)
10.3.3. Germany
10.3.3.1 Germany market estimates and forecast, 2018 – 2030 (USD Million)
10.3.4 France
10.3.4.1 France market estimates and forecast, 2018 – 2030 (USD Million)
10.3.5. Italy
10.3.5.1 Italy market estimates and forecast, 2018 – 2030 (USD Million)
10.3.5 Spain
10.3.5.1 Spain market estimates and forecast, 2018 – 2030 (USD Million)
10.4 Asia Pacific
10.4.1 Asia Pacific Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.4.2 Japan
10.4.2.1 Japan market estimates and forecast, 2018 – 2030 (USD Million)
10.4.3 China
10.4.3.1 China market estimates and forecast, 2018 – 2030 (USD Million)
10.4.4 India
10.4.4.1 India Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.4.5 South Korea
10.4.5.1 South Korea Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.4.6 Australia
10.4.6.1 Australia Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.5 Latin America
10.5.1 Latin America Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.5.2 Brazil
10.5.2.1 Brazil Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.5.3 Mexico
10.5.3.1 Mexico Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.5.4 Argentina
10.5.4.1 Argentina market estimates and forecast, 2018 – 2030 (USD Million)
10.6 Middle East & Africa (MEA)
10.6.1 Middle East & Africa Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.6.1 South Africa
10.6.1.1 South Africa Market Estimates And Forecast, 2018 – 2030 (USD Million)
10.6.2 Saudi Arabia
10.6.2.1 Saudi Arabia market estimates and forecast, 2018 – 2030 (USD Million)
10.6.3 UAE
10.6.3.1 UAE market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 11 Competitive Landscape
11.1 Public Companies
11.1.1 Company Market Position Analysis
11.1.2 Competitive Dashboard Analysis
11.1.3 Strategic Framework
11.2 Private Companies
11.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
11.2.2 Regional Network Map
11.3 Company Profiles
11.3.1 ADVANCED CELL TECHNOLOGY, INC.
11.3.1.1 Company Overview
11.3.1.2 Financial Performance
11.3.1.3 Product Benchmarking
11.3.1.4 Strategic Initiatives
11.3.2 STEMCELL Technologies, Inc.
11.3.2.1 Company Overview
11.3.2.2 Financial Performance
11.3.2.3 Product Benchmarking
11.3.2.4 Strategic Initiatives
11.3.3 CELLULAR ENGINEERING TECHNOLOGIES INC.
11.3.3.1 Company Overview
11.3.3.2 Financial Performance
11.3.3.3 Product Benchmarking
11.3.3.4 Strategic Initiatives
11.3.4 CELLGENIX GmbH
11.3.4.1 Company Overview
11.3.4.2 Financial Performance
11.3.4.3 Product Benchmarking
11.3.4.4 Strategic Initiatives
11.3.5 PROMOCELL GMBH
11.3.5.1 Company Overview
11.3.5.2 Financial Performance
11.3.5.3 Product Benchmarking
11.3.5.4 Strategic Initiatives
11.3.6 LONZA
11.3.6.1 Company Overview
11.3.6.2 Financial Performance
11.3.6.3 Product Benchmarking
11.3.6.4 Strategic Initiatives
11.3.7 KITE PHARMA
11.3.7.1 Company Overview
11.3.7.2 Financial Performance
11.3.7.3 Product Benchmarking
11.3.7.4 Strategic Initiatives
11.3.8 CELLARTIS AB
11.3.8.1 Company Overview
11.3.8.2 Financial Performance
11.3.8.3 Product Benchmarking
11.3.8.4 Strategic Initiatives
11.3.9 ANGEL BIOTECHNOLOGY
11.3.9.1 Company Overview
11.3.9.2 Financial Performance
11.3.9.3 Product Benchmarking
11.3.9.4 Strategic Initiatives
11.3.10 BRAINSTORM CELL THERAPEUTICS
11.3.10.1 Company Overview
11.3.10.2 Financial Performance
11.3.10.3 Product Benchmarking
11.3.10.4 Strategic Initiatives
11.3.11 CELGENE CORPORATION
11.3.11.1 Company Overview
11.3.11.2 Financial Performance
11.3.11.3 Product Benchmarking
11.3.11.4 Strategic Initiatives
11.3.12 OSIRIS THERAPEUTICS, INC.
11.3.12.1 Company Overview
11.3.12.2 Financial Performance
11.3.12.3 Product Benchmarking
11.3.12.4 Strategic Initiatives
11.3.13 GENEA BIOCELLS
11.3.13.1 Company Overview
11.3.13.2 Financial Performance
11.3.13.3 Product Benchmarking
11.3.13.4 Strategic Initiatives
11.3.14 BIOHEART INC.
11.3.14.1 Company Overview
11.3.14.2 Financial Performance
11.3.14.3 Product Benchmarking
11.3.14.4 Strategic Initiatives
11.3.15 WAISMAN BIOMANUFACTURING
11.3.15.1 Company Overview
11.3.15.2 Financial Performance
11.3.15.3 Product Benchmarking
11.3.15.4 Strategic Initiatives
11.3.16 TIGENIX
11.3.16.1 Company Overview
11.3.16.2 Financial Performance
11.3.16.3 Product Benchmarking
11.3.16.4 Strategic Initiatives
11.3.17 CALADRIUS
11.3.17.1 Company Overview
11.3.17.2 Financial Performance
11.3.17.3 Product Benchmarking
11.3.17.4 Strategic Initiatives
11.3.18 GAMIDA CELL.
11.3.18.1 Company Overview
11.3.18.2 Financial Performance
11.3.18.3 Product Benchmarking
11.3.18.4 Strategic Initiatives
11.3.19 PLURISTEM THERAPEUTICS INC.
11.3.19.1 Company Overview
11.3.19.2 Financial Performance
11.3.19.3 Product Benchmarking
11.3.19.4 Strategic Initiatives



★調査レポート[世界の幹細胞市場2022-2030:製品別(成体幹細胞、ヒト胚性幹細胞)、用途別、技術別、治療別、最終用途別、地域別] (コード:GRV22NV085)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の幹細胞市場2022-2030:製品別(成体幹細胞、ヒト胚性幹細胞)、用途別、技術別、治療別、最終用途別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆